## Lesley M Arnold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7369268/publications.pdf

Version: 2024-02-01

47006 28297 13,469 107 47 105 citations h-index g-index papers 110 110 110 10958 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. Seminars in Arthritis and Rheumatism, 2021, 51, 166-174.	3.4	81
2	Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Pain Research, 2020, Volume 13, 3355-3369.	2.0	2
3	Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Current Medical Research and Opinion, 2019, 35, 1825-1835.	1.9	17
4	Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatric Rheumatology, 2019, 17, 27.	2.1	23
5	Response to Wolfe. Letter to the Editor, "Fibromyalgia Criteria― Journal of Pain, 2019, 20, 741-742.	1.4	2
6	Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time. Pain, 2019, 160, 433-441.	4.2	51
7	AAPT Diagnostic Criteria for Fibromyalgia. Journal of Pain, 2019, 20, 611-628.	1.4	222
8	An evidence-based review of pregabalin for the treatment of fibromyalgia. Current Medical Research and Opinion, 2018, 34, 1397-1409.	1.9	21
9	Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms. Arthritis Care and Research, 2017, 69, 1878-1886.	3.4	12
10	Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgraduate Medicine, 2017, 129, 709-714.	2.0	44
11	Dose–response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgraduate Medicine, 2017, 129, 921-933.	2.0	19
12	Fibromyalgia and Chronic Pain Syndromes. Clinical Journal of Pain, 2016, 32, 737-746.	1.9	81
13	Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatric Rheumatology, 2016, 14, 46.	2.1	34
14	Juvenile Fibromyalgia: Different from the Adult Chronic Pain Syndrome?. Current Rheumatology Reports, 2016, 18, 19.	4.7	38
15	Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Pediatric Rheumatology, 2015, 13, 27.	2.1	19
16	Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study. Journal of Rheumatology, 2015, 42, 1237-1244.	2.0	31
17	A Randomized, Placebo-Controlled, Double-Blinded Trial of Duloxetine in the Treatment of General Fatigue in Patients With Chronic Fatigue Syndrome. Psychosomatics, 2015, 56, 242-253.	2.5	15
18	Time to Improvement of Pain and Sleep Quality in Clinical Trials of Pregabalin for the Treatment of Fibromyalgia. Pain Medicine, 2015, 16, 176-185.	1.9	17

#	Article	IF	Citations
19	Psychiatric Disorders in Young Adults Diagnosed with Juvenile Fibromyalgia in Adolescence. Journal of Rheumatology, 2015, 42, 2427-2433.	2.0	32
20	Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Current Medical Research and Opinion, 2014, 30, 2069-2083.	1.9	20
21	Evaluation of the fibromyalgia diagnostic screen in clinical practice. Journal of Evaluation in Clinical Practice, 2014, 20, 158-165.	1.8	13
22	A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Medicine Reviews, 2014, 18, 261-271.	8.5	45
23	Assessment of sleep in patients with fibromyalgia: qualitative development of the fibromyalgia sleep diary. Health and Quality of Life Outcomes, 2014, 12, 111.	2.4	22
24	Long-Term Outcomes of Adolescents With Juvenile-Onset Fibromyalgia in Early Adulthood. Pediatrics, 2014, 133, e592-e600.	2.1	97
25	The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. Journal of Pain, 2014, 15, 241-249.	1.4	159
26	Interpreting Effect Sizes and Clinical Relevance of Pharmacological Interventions for Fibromyalgia. Pain and Therapy, 2013, 2, 65-71.	3.2	10
27	The Fibromyalgia Family Study: A Genomeâ€Wide Linkage Scan Study. Arthritis and Rheumatism, 2013, 65, 1122-1128.	6.7	105
28	A 3-Year, Open-Label, Flexible-Dosing Study of Milnacipran for the Treatment of Fibromyalgia. Clinical Journal of Pain, 2013, 29, 1021-1028.	1.9	21
29	Integrating Health Information Technology and Electronic Health Records Into the Management of Fibromyalgia. Postgraduate Medicine, 2013, 125, 70-77.	2.0	5
30	Influence of Patient Race and Ethnicity on Clinical Assessment in Patients With Affective Disorders. Archives of General Psychiatry, 2012, 69, 593-600.	12.3	88
31	Efficacy and Safety of Duloxetine 30 mg/d in Patients With Fibromyalgia. Clinical Journal of Pain, 2012, 28, 775-781.	1.9	29
32	An Exploratory, Open Trial of Fluoxetine Treatment of Juvenile Fibromyalgia. Journal of Clinical Psychopharmacology, 2012, 32, 293-295.	1.4	16
33	Relationships Among Pain, Depressed Mood, and Global Status in Fibromyalgia Patients: Post Hoc Analyses of a Randomized, Placebo-Controlled Trial of Milnacipran. Psychosomatics, 2012, 53, 371-379.	2.5	16
34	Development and Testing of the Fibromyalgia Diagnostic Screen for Primary Care. Journal of Women's Health, 2012, 21, 231-239.	3.3	32
35	A Framework for Fibromyalgia Management for Primary Care Providers. Mayo Clinic Proceedings, 2012, 87, 488-496.	3.0	130
36	Effect of milnacipran on body weight in patients with fibromyalgia. International Journal of General Medicine, 2012, 5, 879.	1.8	7

#	Article	IF	CITATIONS
37	Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteenâ€week, randomized, doubleâ€blind, placeboâ€controlled, multicenter clinical trial. Arthritis and Rheumatism, 2012, 64, 2387-2397.	6.7	29
38	Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia. Clinical Therapeutics, 2012, 34, 1092-1102.	2.5	24
39	Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, singleâ€blind, randomized, controlled clinical trial. Arthritis and Rheumatism, 2012, 64, 297-305.	6.7	145
40	Development of responder definitions for fibromyalgia clinical trials. Arthritis and Rheumatism, 2012, 64, 885-894.	6.7	42
41	Improving the Recognition and Diagnosis of Fibromyalgia. Mayo Clinic Proceedings, 2011, 86, 457-464.	3.0	182
42	The Science of Fibromyalgia. Mayo Clinic Proceedings, 2011, 86, 907-911.	3.0	252
43	Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Research and Therapy, 2011, 13, R86.	3.5	37
44	Early Improvement in Pain Predicts Pain Response at Endpoint in Patients With Fibromyalgia. Journal of Pain, 2011, 12, 1088-1094.	1.4	14
45	Correlations between Fibromyalgia Symptom and Function Domains and Patient Global Impression of Change: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials of Pregabalin. Pain Medicine, 2011, 12, 260-267.	1.9	22
46	Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care and Research, 2011, 63, 821-826.	3.4	115
47	Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFIâ€20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Selfâ€Report Questionnaire (MASQ). Arthritis Care and Research, 2011, 63, S86-97.	3.4	101
48	Toward Development of a Fibromyalgia Responder Index and Disease Activity Score: OMERACT Module Update. Journal of Rheumatology, 2011, 38, 1487-1495.	2.0	60
49	Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 2010, 32, 1618-1632.	2.5	24
50	Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2010, 62, 2745-2756.	6.7	77
51	Relationship between School Absenteeism and Depressive Symptoms among Adolescents with Juvenile Fibromyalgia. Journal of Pediatric Psychology, 2010, 35, 996-1004.	2.1	103
52	Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial. Journal of Rheumatology, 2010, 37, 2578-2586.	2.0	72
53	The Pathophysiology, Diagnosis and Treatment of Fibromyalgia. Psychiatric Clinics of North America, 2010, 33, 375-408.	1.3	58
54	Fibromyalgia Syndrome: Practical Strategies for Improving Diagnosis and Patient Outcomes. American Journal of Medicine, 2010, 123, S2.	1.5	15

#	Article	IF	CITATIONS
55	Relationships Among Pain and Depressive and Anxiety Symptoms in Clinical Trials of Pregabalin in Fibromyalgia. Psychosomatics, 2010, 51, 489-497.	2.5	32
56	Relationships Among Pain and Depressive and Anxiety Symptoms in Clinical Trials of Pregabalin in Fibromyalgia. Psychosomatics, 2010, 51, 489-497.	2.5	12
57	Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. American Journal of Managed Care, 2010, 16, S138-43.	1.1	14
58	Advances in the Management of Fibromyalgia. CNS Spectrums, 2009, 14, 12-16.	1.2	5
59	What Makes Patients with Fibromyalgia Feel Better? Correlations Between Patient Global Impression of Improvement and Changes in Clinical Symptoms and Function: A Pooled Analysis of 4 Randomized Placebo-controlled Trials of Duloxetine. Journal of Rheumatology, 2009, 36, 2517-2522.	2.0	32
60	Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct. Journal of Rheumatology, 2009, 36, 2318-2329.	2.0	209
61	Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome. Journal of Rheumatology, 2009, 36, 2330-2334.	2.0	66
62	Strategies for Managing Fibromyalgia. American Journal of Medicine, 2009, 122, S31-S43.	1.5	43
63	Comparisons of the Efficacy and Safety of Duloxetine for the Treatment of Fibromyalgia in Patients With Versus Without Major Depressive Disorder. Clinical Journal of Pain, 2009, 25, 461-468.	1.9	31
64	The Pharmacological Treatment of Fibromyalgia. , 2009, , 56-80.		1
65	Pain and the Brain: Chronic Widespread Pain. Journal of Clinical Psychiatry, 2009, 70, e10.	2.2	2
66	Efficacy of Duloxetine in Patients With Fibromyalgia. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 237-244.	0.6	69
67	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis and Rheumatism, 2008, 58, 26-35.	6.7	4,029
68	Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercises. Arthritis and Rheumatism, 2008, 59, 952-960.	6.7	195
69	Patient perspectives on the impact of fibromyalgia. Patient Education and Counseling, 2008, 73, 114-120.	2.2	399
70	Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial â <sup>-</sup> †. Pain, 2008, 136, 432-444.	4.2	323
71	Understanding Fatigue in Major Depressive Disorder and Other Medical Disorders. Psychosomatics, 2008, 49, 185-190.	2.5	96
72	A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia. Journal of Pain, 2008, 9, 792-805.	1.4	253

#	Article	IF	CITATIONS
73	The Effect of Pain on Outcomes in a Trial of Duloxetine Treatment of Major Depressive Disorder. Annals of Clinical Psychiatry, 2008, 20, 187-193.	0.6	19
74	Pain and the Brain. Journal of Clinical Psychiatry, 2008, 69, e25.	2.2	11
75	Evaluating and Diagnosing Fibromyalgia and Comorbid Psychiatric Disorders. Journal of Clinical Psychiatry, 2008, 69, e28.	2.2	31
76	Multidisciplinary Care and Stepwise Treatment for Fibromyalgia. Journal of Clinical Psychiatry, 2008, 69, e35.	2.2	16
77	Use of Antiepileptics in Fibromyalgia. Medical Psychiatry, 2008, , 363-378.	0.2	0
78	A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. Journal of Rheumatology, 2008, 35, 502-14.	2.0	189
79	Management of fibromyalgia and comorbid psychiatric disorders. Journal of Clinical Psychiatry, 2008, 69 Suppl 2, 14-9.	2.2	15
80	Duloxetine for the Treatment of Fibromyalgia in Women: Pooled Results from Two Randomized, Placebo-Controlled Clinical Trials. Journal of Women's Health, 2007, 16, 1145-1156.	3.3	220
81	Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis and Rheumatism, 2007, 56, 1336-1344.	6.7	291
82	Duloxetine and Other Antidepressants in the Treatment of Patients with Fibromyalgia. Pain Medicine, 2007, 8, S63-S74.	1.9	112
83	The Effect of Anxiety and Depression on Improvements in Pain in a Randomized, Controlled Trial of Pregabalin for Treatment of Fibromyalgia. Pain Medicine, 2007, 8, 633-638.	1.9	89
84	Fibromyalgia syndrome. Journal of Rheumatology, 2007, 34, 1415-25.	2.0	129
85	Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Research and Therapy, 2006, 8, 212.	3.5	124
86	Bipolarity in Women: Therapeutic Issues. , 2006, , 235-277.		3
87	Management of psychiatric comorbidity in fibromyalgia. Current Psychiatry Reports, 2006, 8, 241-245.	4.5	8
88	Comorbidity of Fibromyalgia and Psychiatric Disorders. Journal of Clinical Psychiatry, 2006, 67, 1219-1225.	2.2	306
89	Management of Painful Physical Symptoms Associated With Depression and Mood Disorders. CNS Spectrums, 2005, 10, 1-16.	1.2	10
90	A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain, 2005, 119, 5-15.	4.2	395

#	Article	lF	Citations
91	Fibromyalgia syndrome. Journal of Rheumatology, 2005, 32, 2270-7.	2.0	129
92	Family study of fibromyalgia. Arthritis and Rheumatism, 2004, 50, 944-952.	6.7	391
93	A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism, 2004, 50, 2974-2984.	6.7	559
94	Ethnicity and first-rank symptoms in patients with psychosis. Schizophrenia Research, 2004, 67, 207-212.	2.0	80
95	Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophrenia Research, 2004, 66, 169-175.	2.0	42
96	Family study of fibromyalgia and affective spectrum disorder. Biological Psychiatry, 2004, 56, 884-891.	1.3	96
97	Comment on: Familial aggregation of depression in fibromyalgia: a community-based test of alternative hypotheses, Raphael et al., Pain 110 (2004) 449–460. Pain, 2004, 112, 409.	4.2	1
98	Gender differences in bipolar disorder. Psychiatric Clinics of North America, 2003, 26, 595-620.	1.3	208
99	A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. American Journal of Medicine, 2002, 112, 191-197.	1.5	238
100	Phenomenology and therapeutic options for dermatotillomania. Expert Review of Neurotherapeutics, 2002, 2, 725-730.	2.8	3
101	A Placebo-Controlled, Randomized Trial of Fluoxetine in the Treatment of Binge-Eating Disorder. Journal of Clinical Psychiatry, 2002, 63, 1028-1033.	2.2	138
102	Psychogenic Excoriation. CNS Drugs, 2001, 15, 351-359.	5.9	237
103	Ziprasidone: a new atypical antipsychotic. Expert Opinion on Pharmacotherapy, 2001, 2, 1033-1042.	1.8	37
104	Antidepressant Treatment of Fibromyalgia: A Meta-Analysis and Review. Psychosomatics, 2000, 41, 104-113.	2.5	387
105	Reply to "The Nosology of Compulsive Skin Picking". Journal of Clinical Psychiatry, 1999, 60, 618-619.	2.2	9
106	A Case Series of Women With Postpartum-Onset Obsessive-Compulsive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 1999, 1, 103-108.	0.6	36
107	An Open Clinical Trial of Venlafaxine Treatment of Fibromyalgia. Psychosomatics, 1998, 39, 14-17.	2.5	150